NO327165B1 - Rekombinant mistellectin, fremgangsmate for fremstilling derav, nukleinsyre som koder for dette, vektor, vertscelle samt legemiddel og diagnostisk blanding. - Google Patents
Rekombinant mistellectin, fremgangsmate for fremstilling derav, nukleinsyre som koder for dette, vektor, vertscelle samt legemiddel og diagnostisk blanding. Download PDFInfo
- Publication number
- NO327165B1 NO327165B1 NO19976058A NO976058A NO327165B1 NO 327165 B1 NO327165 B1 NO 327165B1 NO 19976058 A NO19976058 A NO 19976058A NO 976058 A NO976058 A NO 976058A NO 327165 B1 NO327165 B1 NO 327165B1
- Authority
- NO
- Norway
- Prior art keywords
- nucleic acid
- acid molecule
- polypeptide
- host
- cell
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims 19
- 108020004707 nucleic acids Proteins 0.000 title claims 18
- 102000039446 nucleic acids Human genes 0.000 title claims 18
- 239000013598 vector Substances 0.000 title claims 6
- 229940079593 drug Drugs 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 239000000539 dimer Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 6
- 230000008827 biological function Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 241000196324 Embryophyta Species 0.000 claims 3
- 241000221012 Viscum Species 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 235000014066 European mistletoe Nutrition 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims 2
- 230000009144 enzymatic modification Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 230000002637 immunotoxin Effects 0.000 claims 2
- 229940051026 immunotoxin Drugs 0.000 claims 2
- 239000002596 immunotoxin Substances 0.000 claims 2
- 231100000608 immunotoxin Toxicity 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000256248 Spodoptera Species 0.000 claims 1
- 241000256251 Spodoptera frugiperda Species 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (21)
1.
Nukleinsyremolekyl, karakterisert ved at (a) koder et preproprotein som etter modning oppviser den biologiske funksjon til mistellektindimeren og oppviser den i figur 4c viste nukleinsyresekvens; (b) koder et fragment av preproproteinet ifølge (a), hvorved fragmentet naturlig er en biologisk aktiv bestanddel av mistellectindimeren; (c) skiller seg fra nukleinsyremolekylet ifølge (a) eller (b) ved degenerering av den genetiske kode; eller (d) hybridiserer under stringente betingelser med nukleinsyremolekylet ifølge (a), (b) eller (c) og koder et polypeptid med den under (a) eller (b) angitte, biologiske funksjon.
2.
Nukleinsyremolekyl ifølge krav 1, karakterisert ved at fragmentet er A-kjeden åv mistellectin som er kodet ved den i figur 4a viste nukleotidsekvens.
3.
Nukleinsyremolekyl ifølge krav 1, karakterisert ved at fragmentet er B-kjeden av mistellectin som er kodet ved den i figur 4b viste nukleotidsekvens.
4.
Nukleinsyremolekyl ifølge ett av kravene 1 til 3, karakterisert ved at det er et DNA-molekyl..
5.
Nukleinsyremolekyl ifølge ett av kravene 1 til 3, karakterisert ved at det er et RNA-molekyl.
6.
Vektor, karakterisert ved at den inneholder minst et nukleinsyremolekyl i henhold til ett av kravene 1 til 4.
Vektor ifølge krav 6, karakterisert ved at det inneholder både et nukleinsyremolekyl ifølge krav 2 eller 4 og et nukleinsyremolekyl ifølge krav 3 eller 4.
8.
Vektor ifølge krav 6 eller 7, karakterisert ved at den er en ekspresjonsvektor.
9.
Vert, karakterisert ved at den er transformert med minst en vektor i henhold til ett av kravene 6 til 8, der den transformerte vert ikke er human, ikke en transgen dyreart, ikke en transgen plante og ikke en transgen plantesort.
10.
Vert ifølge krav 9, karakterisert ved at den er en plantecelle.
11.
Vert ifølge krav 9, karakterisert ved at den er en pattedyrcelle, en bakterie, en soppcelle, en gjærcelle eller en insektscelle.
12.
Vert ifølge krav 11, karakterisert ved at bakterien er E. coli, soppcellen er en Aspargillus-celle og insektscellen er en Spodoptera-celle, fortrinnsvis en Spodoptera frugiperda-celle.
13.
Polypeptid, karakterisert ved at det kodes av nukleinsyremolekylet i henhold til ett av kravene 1 til 5 og produseres av verten i henhold til ett av kravene 11 eller 12, eller som kodes av vektoren ifølge et hvilket som helst av kravene 6 til 8 og fremstilles av verten ifølge krav 11 eller 12 eller som produseres av verten ifølge krav 11 eller 12.
Polypeptid ifølge krav 13, karakterisert ved at det oppviser minst en kjemisk eller enzymatisk modifisering hvorved den enzymatiske modifisering ikke er en glykosylering som forekommer i Viscum-albumin.
15.
Polypeptid ifølge krav 13 eller 14, karakterisert ved at det er et fusjonsprotein.
16.
Polypeptiddimer, karakterisert ved at den har den biologiske funksjon til mistellectin, hvorved den ene monomer kodes av nukleinsyremolekylet ifølge ett av kravene 2,4 eller 5 og den andre monomer kodes av nukleinsyremolekylet ifølge ett av kravene 3 til 5, idet minst en av monomerene produseres av verten i henhold til krav 11 eller 12.
17.
Polypeptiddimer med biologisk funksjon som mistellectin, karakterisert ved at den ene monomer kodes av nukleinsyremolekylet ifølge et hvilket som helst av kravene 2,4 eller 5, og den andre monomeren av nukleinsyremolekylet ifølge et hvilket som helst av kravene 3 til 5, og der minst en av monomerene er et polypeptid ifølge krav 14 eller 15.
18.
Fremgangsmåte for fremstilling av polypeptidet ifølge krav 13 eller polypeptiddimeren ifølge krav 16, karakterisert ved at man dyrker verten i henhold til ett av kravene 9 til 12 under egnede betingelser og isolerer det således oppnådde polypeptid eller polypeptiddimer.
19.
Immuntoksin, karakterisert ved at det omfatter minst et polypeptid ifølge ett av kravene 13 til 15 eller en polypeptiddimer ifølge krav 16 eller 17.
20.
Legemiddel, karakterisert ved at det inneholder polypeptidet ifølge ett av kravene 13 til 15 og/eller polypeptiddimeren ifølge krav 16 eller 17, og/eller immuntoksinet ifølge krav 19, eventuelt sammen med en farmasøytisk godtagbar bærer.
21.
Diagnostisk blanding, karakterisert ved at den i det minste inneholder (a) et nukleinsyremolekylet ifølge ett av kravene 1 til 5; (b) en primer og/eller et primerpar som spesifikt hybridiserer med nukleinsyremolekylet i a) eller en komplementær tråd av denne; og/eller (c) polypeptidet ifølge ett av kravene 13 til 15 og/eller polypeptiddimeren ifølge krav 16 eller 17.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95109949A EP0751221B1 (de) | 1995-06-26 | 1995-06-26 | Rekombinantes Mistellektin (rML) |
| PCT/EP1996/002773 WO1997001636A2 (de) | 1995-06-26 | 1996-06-25 | REKOMBINANTES MISTELLEKTIN (rML) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO976058D0 NO976058D0 (no) | 1997-12-23 |
| NO976058L NO976058L (no) | 1998-02-03 |
| NO327165B1 true NO327165B1 (no) | 2009-05-04 |
Family
ID=8219389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19976058A NO327165B1 (no) | 1995-06-26 | 1997-12-23 | Rekombinant mistellectin, fremgangsmate for fremstilling derav, nukleinsyre som koder for dette, vektor, vertscelle samt legemiddel og diagnostisk blanding. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6271368B1 (no) |
| EP (3) | EP0884388A1 (no) |
| JP (2) | JP3291548B2 (no) |
| KR (1) | KR100292918B1 (no) |
| CN (1) | CN1160457C (no) |
| AR (1) | AR003961A1 (no) |
| AT (1) | ATE170922T1 (no) |
| AU (1) | AU719297B2 (no) |
| BR (1) | BR9609223A (no) |
| CA (1) | CA2225924C (no) |
| CZ (1) | CZ292689B6 (no) |
| DE (1) | DE59503524D1 (no) |
| DK (1) | DK0751221T3 (no) |
| ES (1) | ES2124470T3 (no) |
| HU (1) | HU225738B1 (no) |
| NO (1) | NO327165B1 (no) |
| PL (1) | PL193281B1 (no) |
| RU (1) | RU2241750C2 (no) |
| SK (1) | SK173197A3 (no) |
| WO (1) | WO1997001636A2 (no) |
| ZA (1) | ZA965361B (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0884388A1 (de) * | 1995-06-26 | 1998-12-16 | MADAUS AG Köln | Transgene Pflanzen enthaltend rekombinantes Mistellektin (rML) |
| DE19880004D2 (de) * | 1997-01-02 | 2000-06-15 | B R A I N Biotechnology Resear | Rekombinante Fusionsproteine auf der Basis Ribosomen-inaktivierender Proteine der Mistel Viscum album |
| CN1104438C (zh) * | 1997-06-02 | 2003-04-02 | 山东医科大学附属医院 | 槲寄生提取物及其用途 |
| DE19804210A1 (de) * | 1998-02-03 | 1999-08-12 | Biosyn Arzneimittel Gmbh | Rekombinante Mistellektine |
| KR20010011330A (ko) * | 1999-07-27 | 2001-02-15 | 김종배 | 한국산 겨우살이 추출물과 이로부터 분리한 단백질 및 상기 단백질에서 분리한 렉틴 |
| DE10044027A1 (de) * | 2000-09-06 | 2002-03-14 | Viscum Ag | Rekombinant erzeugtes Mistellektin (ML III) |
| KR100832614B1 (ko) * | 2000-11-14 | 2008-05-27 | 아이언 프라임 | 경구섭취가능한 미슬토 렉틴 제제 및 방법 |
| DE60220068T2 (de) | 2001-07-09 | 2008-01-24 | University Of Copenhagen | Verfahren und ableger für die massenvermehrung von pflanzenparasiten |
| DE10149030A1 (de) * | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
| JP4681226B2 (ja) * | 2001-12-21 | 2011-05-11 | ビスカム・アーゲー | ヤドリギレクチンに対する個体の応答性を判定する方法 |
| DE102011003478A1 (de) * | 2011-02-01 | 2012-08-02 | Cytavis Biopharma Gmbh | Antivirales Mittel enthaltend rekombinante Mistellektine |
| EP2508195A1 (de) * | 2011-04-06 | 2012-10-10 | Cytavis BioPharma GmbH | Arzneimittel enthaltend rekombinante Mistellektine zur Behandlung des malignen Melanoms |
| DK2723374T3 (da) * | 2011-06-27 | 2017-11-20 | Melema Pharma Gmbh | Rekombinant mistelten-lektin og dettes anvendelse som adjuvans |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3205348A1 (de) * | 2016-02-15 | 2017-08-16 | Melema Pharma GmbH | Arzneimittel enthaltend rekombinante mistellektine zur behandlung von hirntumoren |
| CN106166223A (zh) * | 2016-09-17 | 2016-11-30 | 四川易创生物科技有限公司 | 一种治疗肺肾阴亏、潮热盗汗的中药组合物及其制备方法 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| CN115025207B (zh) * | 2022-06-23 | 2023-02-07 | 黑龙江中医药大学 | 一种用于治疗类风湿性关节炎的药物及其制备方法 |
| CN117924453B (zh) * | 2024-03-19 | 2024-08-06 | 广东现代汉方科技有限公司 | 一种甘露糖特异性凝集素重组植物蛋白的制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127532A (en) * | 1989-09-12 | 2000-10-03 | Board Of Trustees Operating Michigan State University | Lectin cDNA and transgenic plants derived therefrom |
| US5407454A (en) * | 1989-11-07 | 1995-04-18 | Pioneer Hi-Bred International, Inc. | Larvicidal lectins and plant insect resistance based thereon |
| DE4221836A1 (de) * | 1992-07-03 | 1994-01-05 | Gabius Hans Joachim Prof Dr | Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator |
| DE4341476A1 (de) * | 1993-12-02 | 1995-06-08 | Uwe Dr Pfueller | Mittel zur Untersuchung und Beeinflussung zellulärer Veränderungen auf Lektinbasis |
| EP0884388A1 (de) * | 1995-06-26 | 1998-12-16 | MADAUS AG Köln | Transgene Pflanzen enthaltend rekombinantes Mistellektin (rML) |
-
1995
- 1995-06-26 EP EP98105660A patent/EP0884388A1/de not_active Withdrawn
- 1995-06-26 AT AT95109949T patent/ATE170922T1/de active
- 1995-06-26 DK DK95109949T patent/DK0751221T3/da active
- 1995-06-26 ES ES95109949T patent/ES2124470T3/es not_active Expired - Lifetime
- 1995-06-26 DE DE59503524T patent/DE59503524D1/de not_active Expired - Lifetime
- 1995-06-26 EP EP95109949A patent/EP0751221B1/de not_active Expired - Lifetime
-
1996
- 1996-05-31 CN CNB961960256A patent/CN1160457C/zh not_active Expired - Fee Related
- 1996-06-25 US US08/776,059 patent/US6271368B1/en not_active Expired - Lifetime
- 1996-06-25 HU HU9900316A patent/HU225738B1/hu not_active IP Right Cessation
- 1996-06-25 KR KR1019970709890A patent/KR100292918B1/ko not_active IP Right Cessation
- 1996-06-25 BR BR9609223A patent/BR9609223A/pt not_active Application Discontinuation
- 1996-06-25 CA CA002225924A patent/CA2225924C/en not_active Expired - Fee Related
- 1996-06-25 SK SK1731-97A patent/SK173197A3/sk unknown
- 1996-06-25 RU RU98101194/13A patent/RU2241750C2/ru not_active IP Right Cessation
- 1996-06-25 WO PCT/EP1996/002773 patent/WO1997001636A2/de active IP Right Grant
- 1996-06-25 ZA ZA9605361A patent/ZA965361B/xx unknown
- 1996-06-25 AU AU64163/96A patent/AU719297B2/en not_active Ceased
- 1996-06-25 JP JP50416997A patent/JP3291548B2/ja not_active Expired - Fee Related
- 1996-06-25 CZ CZ19974049A patent/CZ292689B6/cs not_active IP Right Cessation
- 1996-06-25 PL PL324209A patent/PL193281B1/pl not_active IP Right Cessation
- 1996-06-25 EP EP96923926A patent/EP0835312A2/de not_active Withdrawn
- 1996-06-26 AR ARP960103316A patent/AR003961A1/es unknown
-
1997
- 1997-12-23 NO NO19976058A patent/NO327165B1/no not_active IP Right Cessation
-
2001
- 2001-12-28 JP JP2001401821A patent/JP2002300890A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327165B1 (no) | Rekombinant mistellectin, fremgangsmate for fremstilling derav, nukleinsyre som koder for dette, vektor, vertscelle samt legemiddel og diagnostisk blanding. | |
| DE69334197T2 (de) | Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik | |
| CN102239183B (zh) | 大量分泌的蛋白的筛选和它们作为融合配偶体在重组蛋白制备中应用 | |
| DE3785864T2 (de) | Verfahren zur Herstellung von menschlichem Epidermalwachstumsfaktor und dessen Analogen. | |
| DE69233008T2 (de) | Fusionierung von Peptiden und Proteinen mit Thioredoxin und thioredoxin-ähnlichen Molekülen | |
| EP1222207B1 (de) | C-peptid zur verbesserten herstellung von insulin und insulinanaloga | |
| RU98101194A (ru) | Рекомбинантный лектин омелы белой (rml) | |
| AU704515C (en) | Novel protein and process for producing the same | |
| Engel et al. | Isolation and cloning of Omp alpha, a coiled‐coil protein spanning the periplasmic space of the ancestral eubacterium Thermotoga maritima. | |
| CA2030108C (en) | Process for the preparation of genetic vectors for the expression of nerve growth factor in eukaryotic cells | |
| JPS62500074A (ja) | バチルス スリンギエンシス 結晶タンパク質遺伝子毒素セグメント | |
| KR900014428A (ko) | 신규폴리펩타이드 및 그 제조방법 | |
| ATE268383T1 (de) | Interferon gene aus voegeln und rekombinante dna | |
| KR870010193A (ko) | 인체 췌장 엘라스타제 i | |
| US5218093A (en) | EGF variants and pharmaceutical use thereof | |
| CN1254379A (zh) | 通过使用融合蛋白生产酰胺化肽的方法 | |
| KR910006483A (ko) | 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도 | |
| Negro et al. | Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli | |
| WO2004057003A3 (de) | Verfahren zur herstellung von aminosäuren mittels transgener organismen | |
| DE19717893A1 (de) | Monofunktionelle Glycosyltransferasen | |
| DE3751081T2 (de) | [Leu 13] Motilin, dessen kodierende DNS-Moleküle und Verfahren zu dessen Herstellung. | |
| DE69111371T2 (de) | Synthetisches Gen für menschliches Parathyroidhormon. | |
| CA2045839A1 (en) | Cloned n-methylhydantoinase | |
| MX9206265A (es) | Procedimiento biosintetico para la preparacion de compuestos quimicos. | |
| DE3786870T2 (de) | Methode zur Herstellung von Proteinen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |